Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Single-blind, Active-controlled, Phase 1/2 Study to Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome (Mucopolysaccharidosis II) Patients

NCT01301898 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.

NCT NCT01301898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01301898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Single-blind, Active-controlled, Phase 1/2 Study to Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome (Mucopolysaccharidosis II) Patients
Lead sponsor
Green Cross Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2010
Completion date
March 31, 2011
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis ii